Skip Navigation


Human Reproduction Update Advance Access originally published online on May 3, 2006
Human Reproduction Update 2006 12(5):513-518; doi:10.1093/humupd/dml021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
12/5/513    most recent
dml021v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Weisz, B.
Right arrow Articles by Rodeck, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weisz, B.
Right arrow Articles by Rodeck, C. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

An update on antenatal screening for Down’s syndrome and specific implications for assisted reproduction pregnancies

Boaz Weisz1,3 and Charles H. Rodeck2

1 Department of Obstetrics and Gynaecology, Sheba Medical Center, Tel-Hashomer, Israel and 2 Department of Obstetrics and Gynaecology, University College London, London, UK

3 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Sheba Medical Center, Tel-Hashomer 52321, Israel. E-mail: boazmd{at}zahav.net.il

Since the introduction of antenatal serum screening for Down’s syndrome (DS) more than two decades ago, several screening approaches have been utilized in routine clinical practice. The current DS screening strategies involve mid-trimester serum biochemistry tests, first trimester tests combining sonographic markers and serum biochemistry and integration of first and second trimester markers. In this review, we evaluate the performance of DS screening strategies according to the Serum, Urine and Ultrasound Screening Study (SURUSS), the First and Second Trimester Evaluation of Risks (FASTER) Trial and the Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study. We also evaluate the performance of first trimester screening in studies and meta-analyses by other groups. Specific issues related to assisted reproduction technology (ART) pregnancies are also addressed in this review.

Key words: Down’s syndrome / integrated screening / nuchal translucency / screening


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
M.A. Durand, J. Boivin, and G. Elwyn
A review of decision support technologies for amniocentesis
Hum. Reprod. Update, September 4, 2008; (2008) dmn037v1.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A.C. Gjerris, A. Loft, A. Pinborg, M. Christiansen, and A. Tabor
Prenatal testing among women pregnant after assisted reproductive techniques in Denmark 1995-2000: a national cohort study
Hum. Reprod., July 1, 2008; 23(7): 1545 - 1552.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.